PATENT CLAIM ANALYSIS

Application Number: 16243926
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "04400A"]

Abstract:
Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.

Claim (Index 66):
An antisense oligonucleotide of 21 bases comprising a base sequence that is 100% complementary to 21 consecutive bases of exon 53 of the human dystrophin pre-mRNA,\n wherein the base sequence comprises 19 consecutive bases of (SEQ\u2003ID\u2003NO:\u2003431) CTGTTGCCTCCGGTTCTGAAGGTGT, wherein the antisense oligonucleotide is a morpholino oligomer, and wherein the antisense oligonucleotide induces exon 53 skipping; or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 99.0
- Lexical Diversity: 1.10345
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14852264', '14857569', '14852257', '14858416', '14857590']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7035449110930165
- 35 USC 102 Novelty (BERT): 0.6220704795996779
- Combined Prediction Score: 0.6953974679436827
- Mean Citation Score: 574.9887580000002
- Max Citation Score: 575.6781599999998
- Similarity Product: 511.1605908872364

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test